1. Real‐world use of venetoclax in the treatment of paediatric and teenage/young adult haematological malignancies.
- Author
-
Wilson, Abbie, Moussa, Ahmed, Trinquand, Amélie, Malone, Andrea, Tewari, Sanjay, Calvert, Richard, Patrick, Katharine, Nicholson, Emma, Smith, Katy, Grandage, Victoria, Baird, Susan, George, Lindsay, Qureshi, Amrana, Borg, Albert, Gibson, Brenda, Patel, Pritesh, Bartram, Jack, Samrin, Lamia, and O'Connor, David
- Subjects
MYELOID leukemia ,YOUNG adults ,ACUTE leukemia ,VENETOCLAX ,OVERALL survival - Abstract
Summary: Early‐phase trials of venetoclax in children and teenagers/young adults with leukaemia have yielded promising results, but there remains a paucity of real‐world data. To address this, we report a cohort of 41 children treated with venetoclax for a range of haematological malignancies, demonstrating complete remission in 43.6%, with most achieving minimal residual disease (MRD) negativity. Venetoclax was particularly effective as a bridge to transplant, with bridging successful in 75% of patients. Patients with MRD <1% at initiation of venetoclax were more likely to achieve MRD negativity (81.8% vs. 34.5%, p = 0.007) and had improved overall survival (54.5% vs. 17.9%, p = 0.004). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF